NRC FORM 374

PAGE 1 OF 3 PAGES Amendment No. 11

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Excelsior Springs Hospital				In accordance with application dated April 17, 2020,		4. Expiration Date: November 30, 2036	
2.	1700 Rainbow Blvd. Excelsior Springs, MO	64024	ESAC	3. License No. is renewed as follows:	: 24-32234-01 in its entirety to read		ket No.: 030-35302 prence No.:
6.	Byproduct, source, and/or special nuclear material	7.	Chemical and/or physical	form 8.	Maximum amount that licens may possess at any one tim under this license		Authorized use
A.	Any byproduct material permitted by 10 CFR 35.100	A.	Any O	Α.	As needed	А.	For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
В.	Any byproduct material permitted by 10 CFR 35.200	В.	Any	B.	As needed	В.	For use in imaging and localization studies permitted by 10 CFR 35.200.
C.	Any byproduct material permitted by 10 CFR 35.300	C.	Any	C.	2 curies total	C.	For any use permitted by 10 CFR 35.300.
D.	Any byproduct material permitted by 10 CFR 31.11	D.	Any	D.	50 millicuries total	D.	For use in in-vitro studies.

	U.S. NUCLEAR REGULATORY	COMMISSION	PAGE 2 OF 3 PAGES
MATERIALS LICENSE	License No.: 24-32234-01	Docket or Reference No.: 030-35302	
SUPPLEMENTARY SHEET	Amendment No. 11		
	CONDITIONS	 }	
10. Licensed material may be used or sto	red at the licensee's facilities located a	at 1700 Rainbow Blvd., Excelsior Springs	, Missouri, 64024.
11. The Radiation Safety Officer (RSO) for	or this license is Michaelle A. Warner, (CNMT.	
	22	0	
12. Licensed material shall only be used I	by, or under the supervision of:	32	
A. Individuals permitted to work as a	uthorized users in accordance with 10	CFR 35.13 and 10 CFR 35.14.	
		<u> </u>	
B. The following individuals are auth	orized users for the material and medi	cal uses as indicated:	
	S States and States an		
Authorized User	Material and Use		
Daniel H. Dunker, M.D.	10 CFR 31.11,10 CFR 35.100,	10 CFR 35.200	
Stephen Gimple, M.D.	10 CFR 31.11,10 CFR 35.200		
Zafir A. Hawa, M.D.	10 CFR 31.11,10 CFR 35.200	10	
Kevin C. Jones, D.O.	10 CFR 31.11,10 CFR 35.200		
Christine Keesling, M.D.		10 CFR 35.200,10 CFR 35.300 (limited to	o oral administration
-	of sodium iodide I-131 and stro		o oral administration
James H. Mitchell, M.D.	of sodium iodide I-131 and stro 10 CFR 31.11,10 CFR 35.200	ntium Sr-89)	o oral administration
James H. Mitchell, M.D. Randall C. Newth, M.D.	of sodium iodide I-131 and stro 10 CFR 31.11,10 CFR 35.200 10 CFR 31.11,10 CFR 35.100,	ntium Sr-89) 10 CFR 35.200	
James H. Mitchell, M.D. Randall C. Newth, M.D. Robert Newth, M.D.	of sodium iodide I-131 and stro 10 CFR 31.11,10 CFR 35.200 10 CFR 31.11,10 CFR 35.100, 10 CFR 31.11, 10 CFR 35.100, of sodium iodide I-131 and stro	ntium Sr-89) 10 CFR 35.200 ,10 CFR 35.200,10 CFR 35.300 (limited to	
James H. Mitchell, M.D. Randall C. Newth, M.D. Robert Newth, M.D. Aaron Notestine, M.D.	of sodium iodide I-131 and stro 10 CFR 31.11,10 CFR 35.200 10 CFR 31.11,10 CFR 35.100, 10 CFR 31.11, 10 CFR 35.100, of sodium iodide I-131 and stro 10 CFR 31.11,10 CFR 35.200	ntium Sr-89) 10 CFR 35.200 ,10 CFR 35.200,10 CFR 35.300 (limited to ntium Sr-89)	o oral administration
James H. Mitchell, M.D. Randall C. Newth, M.D. Robert Newth, M.D.	of sodium iodide I-131 and stro 10 CFR 31.11,10 CFR 35.200 10 CFR 31.11,10 CFR 35.100, 10 CFR 31.11, 10 CFR 35.100, of sodium iodide I-131 and stro 10 CFR 31.11,10 CFR 35.200	ntium Sr-89) 10 CFR 35.200 10 CFR 35.200,10 CFR 35.300 (limited to ntium Sr-89) 10 CFR 35.200,10 CFR 35.300 (limited to	o oral administration

NRC FORM 374A	U.S. NUCLEAR REGULATORY C	OMMISSION	PAGE 3 OF 3 PAGES						
MATERIALS LICENSE	License No.: 24-32234-01	Docket or Reference No.: 030-35302							
SUPPLEMENTARY SHEET	Amendment No. 11								
Authorized User									
Dwarakraj Soundarraj, M.D.	10 CFR 31.11,10 CFR 35.200	1,							
 13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition applies onto limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations. A. Application dated April 17, 2020 (ML20113E920) B. Letter dated November 9, 2021 (ML21314A560) FOR THE U. S. NUCLEAR REGULATORY COMMISSION 									
Date: <u>November 10, 2021</u>	E	y: Bryan A. Parker Region III							